-
Company Insights
Innovation and Patenting activity of Heidelberger Druckmaschinen AG Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Heidelberger Druckmaschinen AG Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Analyst Opinions
Net Zero by 2050 – Industrial Decarbonization Gains Momentum (Vol.2)
Net Zero by 2050 Overview Businesses and tech giants globally are focusing on low-carbon products, renewables, and EVs to achieve net zero emissions. Key sectors such as aerospace, automotive, and technology are advancing sustainability through innovations in hydrogen, EVs, fuel cells, and smart energy solutions among others. The “Net Zero by 2050” report outlines decarbonization-related deals value and volume trends, VC investment activity and geographic trends, and leading investors. The report also provides facts and figures related to climate change,...
-
Product Insights
Herpes Labialis (Oral Herpes) – Drugs In Development, 2023
Global Markets Direct’s, ‘Herpes Labialis (Oral Herpes) - Drugs In Development, 2023’, provides an overview of the Herpes Labialis (Oral Herpes) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Herpes Labialis (Oral Herpes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Genital Herpes – Drugs In Development, 2023
Global Markets Direct’s, ‘Genital Herpes - Drugs In Development, 2023’, provides an overview of the Genital Herpes pipeline landscape. The report provides comprehensive information on the therapeutics under development for Genital Herpes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Kidney Transplant Rejection – Drugs In Development, 2023
Global Markets Direct’s, ‘Kidney Transplant Rejection - Drugs In Development, 2023’, provides an overview of the Kidney Transplant Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Simplexvirus (HSV) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Simplexvirus (HSV) Infections - Drugs In Development, 2023’, provides an overview of the Simplexvirus (HSV) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Simplexvirus (HSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Dengue Fever – Drugs In Development, 2023
Global Markets Direct’s, ‘Dengue Fever - Drugs In Development, 2023’, provides an overview of the Dengue Fever pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dengue Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Cytomegalovirus (HHV-5) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Cytomegalovirus (HHV-5) Infections - Drugs In Development, 2023’, provides an overview of the Cytomegalovirus (HHV-5) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Refractory Chronic Lymphocytic Leukemia (CLL) – Drugs In Development, 2023
Global Markets Direct’s, ‘Refractory Chronic Lymphocytic Leukemia (CLL) - Drugs In Development, 2023’, provides an overview of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Relapsed Chronic Lymphocytic Leukemia (CLL) – Drugs In Development, 2023
Global Markets Direct’s, ‘Relapsed Chronic Lymphocytic Leukemia (CLL) - Drugs In Development, 2023’, provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...